Company: IMRX
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001790340-25-000104
Chunk: 318

Company: Immuneering Corp
Filing Date: 2025-08-13
Form: 10-Q
Item: Part II, Item 5
Chunk 318
---
Item 5. Other Information

(a) Disclosure in lieu of reporting on a Current Report on Form 8-K.

      On August 11, 2025, Ann Berman notified the Company of her intent to resign from the Company's Board of Directors and its committees in order to allocate additional time to her professional responsibilities as the new chair of Beth Israel Deaconess Medical Center, with such resignation to become effective on or before October 1, 2025. Ms. Berman's resignation was not due to any disagreement on any matter relating to the Company's operations, policies or practices.

(b) Material changes to the procedures by which security holders may recommend nominees to the board of directors.

      None.

(c) Insider Trading Arrangements and Policies

During the three months ended June 30, 2025, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408(a) of Regulation S-K.

93